Delivering affordable cancer care in high-income countries
Published September 26, 2011
Executive summaryThe burden of cancer is growing rapidly, and the disease is becoming a major challenge for all developed countries. This is not simply due to an increase in absolute numbers or need for optimised treatments, rather it relates to the unsustainable rate of increase in expenditure on cancer within health-care systems. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high-quality and equitable care? In this Commission and the linked Comments, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer-care in high-income countries.CommentsRegulators, payers, and prescribers: can we fill the gaps?
Francesco Pignatti, Xavier Luria, Eric Abadie, Hans-Georg EichlerFull Text | PDFThe opportunity cost of cancer care: a statement from NICE
Michael D Rawlins, Kalipso ChalkidouFull Text | PDFThe Lancet Oncology CommissionDelivering affordable cancer care in high-income countries
Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg, Mark De Ridder, Susan A McCloskey, Dirk Verellen, Terence Roberts, Guy Storme, Rodney J Hicks, Peter J Ell, Bradford R Hirsch, David P Carbone, Kevin A Schulman, Paul Catchpole, David Taylor, Jan Geissler, Nancy G Brinker, David Meltzer, David Kerr, Matti AaproSummary | Full Text | PDF